Consequently, targeting these pathways, such as inhibiting the writer METTL3, erasers FTO/ALKBH5, or knocking down YTHDF3, represents a prospective therapeutic approach for melanoma progression and overcoming chemoresistance. Here, METTL3 is linked to melanoma.